81 Recruiting Anatomic Stage III Breast Cancer AJCC v8 Clinical Trials
Explore open interventional and observational research studies actively enrolling participants across the USA. Verify eligibility and contact site coordinators directly.
📍 Find Near Me by DistanceBrowse by State
Top Recruiting Anatomic Stage III Breast Cancer AJCC v8 Studies
Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors
📍 Keck Medicine of USC Koreatown — Los Angeles, California
View Study & Checklist ➔Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer
📍 Siteman Cancer Center at Washington University — St Louis, Missouri
View Study & Checklist ➔Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
📍 Mayo Clinic in Florida — Jacksonville, Florida
View Study & Checklist ➔Tamoxifen and Pegylated Liposomal Doxorubicin for the Treatment of Patients With Metastatic or Inoperable, Locally Advanced Triple Negative Breast Cancer
📍 Roswell Park Cancer Institute — Buffalo, New York
View Study & Checklist ➔Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic
📍 University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
View Study & Checklist ➔Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations
📍 UF Health Cancer Institute - Gainesville — Gainesville, Florida
View Study & Checklist ➔Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer
📍 Dana-Farber Cancer Institute — Boston, Massachusetts
View Study & Checklist ➔Testing Olaparib Either Alone or in Combination With Atezolizumab in BRCA Mutant Non-HER2-positive Breast Cancer
📍 Mayo Clinic Hospital in Arizona — Phoenix, Arizona
View Study & Checklist ➔Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer
📍 Boston Medical Center — Boston, Massachusetts
View Study & Checklist ➔Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer
📍 City of Hope Comprehensive Cancer Center — Duarte, California
View Study & Checklist ➔Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer
📍 Fred Hutch/University of Washington Cancer Consortium — Seattle, Washington
View Study & Checklist ➔Propranolol and Pembrolizumab for Tumor Re-sensitization and Treatment of Patients With Checkpoint Inhibitor Refractory Metastatic or Unresectable Triple Negative Breast Cancer
📍 Emory University Hospital — Atlanta, Georgia
View Study & Checklist ➔Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast Cancer
📍 University of California Davis Comprehensive Cancer Center — Sacramento, California
View Study & Checklist ➔SHAPE Neoadjuvant Chemotherapy Response
📍 Mayo Clinic — Rochester, Minnesota
View Study & Checklist ➔Lymphovenous Bypass Procedure Before Underarm Lymph Node Surgery in Preventing Lymphedema in Patients With Inflammatory or Locally Advanced Non-inflammatory Breast Cancer or Melanoma
📍 M D Anderson Cancer Center — Houston, Texas
View Study & Checklist ➔